Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer

Immune checkpoint inhibitors can affect any organ, including the salivary glands. A case of Sjögren's syndrome (SjS) induced by nivolumab for the treatment of gastric cancer is herein presented. Nivolumab treatment caused marked tumor shrinkage, but xerostomia developed after two cycles. It too...

Descripción completa

Detalles Bibliográficos
Autores principales: Higashi, Tetsuo, Miyamoto, Hideaki, Yoshida, Ryoji, Furuta, Yoki, Nagaoka, Katsuya, Naoe, Hideaki, Naito, Hisaki, Nakayama, Hideki, Tanaka, Motohiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662059/
https://www.ncbi.nlm.nih.gov/pubmed/32581160
http://dx.doi.org/10.2169/internalmedicine.4701-20
_version_ 1783609320510849024
author Higashi, Tetsuo
Miyamoto, Hideaki
Yoshida, Ryoji
Furuta, Yoki
Nagaoka, Katsuya
Naoe, Hideaki
Naito, Hisaki
Nakayama, Hideki
Tanaka, Motohiko
author_facet Higashi, Tetsuo
Miyamoto, Hideaki
Yoshida, Ryoji
Furuta, Yoki
Nagaoka, Katsuya
Naoe, Hideaki
Naito, Hisaki
Nakayama, Hideki
Tanaka, Motohiko
author_sort Higashi, Tetsuo
collection PubMed
description Immune checkpoint inhibitors can affect any organ, including the salivary glands. A case of Sjögren's syndrome (SjS) induced by nivolumab for the treatment of gastric cancer is herein presented. Nivolumab treatment caused marked tumor shrinkage, but xerostomia developed after two cycles. It took 3 months after symptom onset to confirm the diagnosis of SjS. Prednisolone and pilocarpine hydrochloride did not relieve the symptoms. SjS is a relatively rare immune-related adverse event that might sometimes be overlooked. Since SjS can severely impair a patient's quality of life, oncologists should not miss any signs of salivary gland hypofunction and cooperate with specialists for SjS.
format Online
Article
Text
id pubmed-7662059
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-76620592020-11-25 Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer Higashi, Tetsuo Miyamoto, Hideaki Yoshida, Ryoji Furuta, Yoki Nagaoka, Katsuya Naoe, Hideaki Naito, Hisaki Nakayama, Hideki Tanaka, Motohiko Intern Med Case Report Immune checkpoint inhibitors can affect any organ, including the salivary glands. A case of Sjögren's syndrome (SjS) induced by nivolumab for the treatment of gastric cancer is herein presented. Nivolumab treatment caused marked tumor shrinkage, but xerostomia developed after two cycles. It took 3 months after symptom onset to confirm the diagnosis of SjS. Prednisolone and pilocarpine hydrochloride did not relieve the symptoms. SjS is a relatively rare immune-related adverse event that might sometimes be overlooked. Since SjS can severely impair a patient's quality of life, oncologists should not miss any signs of salivary gland hypofunction and cooperate with specialists for SjS. The Japanese Society of Internal Medicine 2020-06-23 2020-10-15 /pmc/articles/PMC7662059/ /pubmed/32581160 http://dx.doi.org/10.2169/internalmedicine.4701-20 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Higashi, Tetsuo
Miyamoto, Hideaki
Yoshida, Ryoji
Furuta, Yoki
Nagaoka, Katsuya
Naoe, Hideaki
Naito, Hisaki
Nakayama, Hideki
Tanaka, Motohiko
Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer
title Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer
title_full Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer
title_fullStr Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer
title_full_unstemmed Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer
title_short Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer
title_sort sjögren's syndrome as an immune-related adverse event of nivolumab treatment for gastric cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662059/
https://www.ncbi.nlm.nih.gov/pubmed/32581160
http://dx.doi.org/10.2169/internalmedicine.4701-20
work_keys_str_mv AT higashitetsuo sjogrenssyndromeasanimmunerelatedadverseeventofnivolumabtreatmentforgastriccancer
AT miyamotohideaki sjogrenssyndromeasanimmunerelatedadverseeventofnivolumabtreatmentforgastriccancer
AT yoshidaryoji sjogrenssyndromeasanimmunerelatedadverseeventofnivolumabtreatmentforgastriccancer
AT furutayoki sjogrenssyndromeasanimmunerelatedadverseeventofnivolumabtreatmentforgastriccancer
AT nagaokakatsuya sjogrenssyndromeasanimmunerelatedadverseeventofnivolumabtreatmentforgastriccancer
AT naoehideaki sjogrenssyndromeasanimmunerelatedadverseeventofnivolumabtreatmentforgastriccancer
AT naitohisaki sjogrenssyndromeasanimmunerelatedadverseeventofnivolumabtreatmentforgastriccancer
AT nakayamahideki sjogrenssyndromeasanimmunerelatedadverseeventofnivolumabtreatmentforgastriccancer
AT tanakamotohiko sjogrenssyndromeasanimmunerelatedadverseeventofnivolumabtreatmentforgastriccancer

Ejemplares similares